Thrombotic Microangiopathy in Inverted Formin 2â€“M

Journal of the American Society of Nephrology: JASN
28, 1084-1091
DOI: 10.1681/asn.2015101189

Citation Report

#	Article	IF	Citations
1	Inverted formins: A subfamily of atypical formins. Cytoskeleton, 2017, 74, 405-419.	1.0	17
2	Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. CKJ: Clinical Kidney Journal, 2017, 10, 600-624.	1.4	44
3	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Internal Medicine Journal, 2018, 48, 624-636.	0.5	26
4	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology, 2018, 23, 507-517.	0.7	21
5	Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2018, 71, 287-290.	2.1	4
6	Diseases of complement dysregulationâ€"an overview. Seminars in Immunopathology, 2018, 40, 49-64.	2.8	83
7	Thrombotic Microangiopathy and the Kidney. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 300-317.	2.2	234
8	The genetics of atypical hemolytic uremic syndrome. Medizinische Genetik, 2018, 30, 400-409.	0.1	33
9	Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 2809-2819.	3.0	50
10	Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatric Nephrology, 2019, 34, 1465-1482.	0.9	47
11	Human Pathobiochemistry. , 2019, , .		0
12	The Role of Complement in the Pathogenesis of HUS and the TMA Spectrum Disorders. Current Pediatrics Reports, 2019, 7, 1-11.	1.7	3
13	Pathogenesis of Atypical Hemolytic Uremic Syndrome. Journal of Atherosclerosis and Thrombosis, 2019, 26, 99-110.	0.9	53
14	CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2020, 31, 241-256.	3.0	57
15	The formin INF2 in disease: progress from 10Âyears of research. Cellular and Molecular Life Sciences, 2020, 77, 4581-4600.	2.4	25
16	FSGS-Causing INF2 Mutation Impairs Cleaved INF2 N-Fragment Functions in Podocytes. Journal of the American Society of Nephrology: JASN, 2020, 31, 374-391.	3.0	17
17	Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney International, 2020, 97, 1260-1274.	2.6	31
18	Genetic Disorders of the Glomerular Filtration Barrier. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1818-1828.	2.2	32

#	Article	IF	Citations
19	Inherited Kidney Complement Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 942-956.	2.2	34
20	Complement testing in the clinical laboratory. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 447-478.	2.7	4
21	Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nature Reviews Nephrology, 2021, 17, 543-553.	4.1	64
22	Formins in Human Disease. Cells, 2021, 10, 2554.	1.8	16
24	Haemolytic uremic syndrome: diagnosis and management. F1000Research, 2019, 8, 1690.	0.8	23
25	A Deregulated Stress Response Underlies Distinct INF2-Associated Disease Profiles. Journal of the American Society of Nephrology: JASN, 2020, 31, 1296-1313.	3.0	20
27	Hereditary Proteinuric Glomerular Disorders. , 2019, , 223-239.		0
28	Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. Journal of Molecular Medicine, 2021, , 1.	1.7	6
31	Clinical Aspects of Genetic Forms of Nephrotic Syndrome. , 2022, , 301-325.		2
32	Diagnosis and treatment of thrombotic microangiopathy. International Journal of Laboratory Hematology, 2022, 44, 101-113.	0.7	15
33	Atypical hemolytic-uremic syndrome: evolution of treatment and impact of clinical and genetic characteristics on possibility of eculizumab withdrawal. Nephrology (Saint-Petersburg), 2022, 26, 19-29.	0.1	0
34	How I treat thrombotic microangiopathy in the era ofÂrapid genomics. Blood, 2023, 141, 147-155.	0.6	5
36	Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome. Transplantation, 2023, 107, 994-1003.	0.5	6
37	Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome. Pediatric Nephrology, 2023, 38, 2659-2668.	0.9	2
38	Atypical Hemolytic Uremic Syndrome. , 2023, , 605-639.		0